---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-152866"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:47.016587+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene Therapeutics launches underwritten public offering, suspends ATM sales

## Summary
- Company announced proposed underwritten public offering of common stock on April 13, 2026.
- Sales under existing ATM agreement with TD Securities are suspended pending new prospectus.
- No offering size or pricing details disclosed in the 8-K; further supplement expected.
- Proceeds intended for general corporate purposes; dilution to existing shareholders anticipated.

## SEC filing metadata
- accession: 0001193125-26-152866
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000119312526152866/0001193125-26-152866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000119312526152866/d249901d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-152866
- JSON: https://secwatch.observer/filing/0001193125-26-152866.json
- Plain text: https://secwatch.observer/filing/0001193125-26-152866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.